Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
arcticnovartis
Thu, 07/03/2025 – 07:19
Read more about Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
…
Novartis completes acquisition of Regulus Therapeutics
arcticnovartis
Wed, 06/25/2025 – 15:19
Read more about Novartis completes acquisition of Regulus Therapeutics
Basel, June 25, 2025 – Novartis today announced that it has succes…
Novartis completes acquisition of Regulus Therapeutics
arcticnovartis
Wed, 06/25/2025 – 15:19
Read more about Novartis completes acquisition of Regulus Therapeutics
Basel, June 25, 2025 – Novartis today announced that it has succes…
Novartis announces expiration of Regulus Therapeutics tender offer
arcticnovartis
Wed, 06/25/2025 – 07:04
Read more about Novartis announces expiration of Regulus Therapeutics tender offer
Basel, June 25, 2025 – Novartis today anno…
Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer
arcticnovartis
Mon, 06/23/2025 – 07:04
Read more about Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer
…
Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer
arcticnovartis
Mon, 06/23/2025 – 07:04
Read more about Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer
…
Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH
arcticnovartis
Thu, 06/12/2025 – 08:04
Read more about Novartis Fabhalta® shows statistically significan…
Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH
arcticnovartis
Thu, 06/12/2025 – 08:04
Read more about Novartis Fabhalta® shows statistically significan…
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
arcticnovartis
Mon, 06/02/2025 – 07:19
Read more about Novartis Pluvicto™ …
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis
arcticnovartis
Sun, 06/01/2025 – 15:04
Read more about Novartis Kisqali® reduces risk of recurrence in younger patients with ear…
